CPMG

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

Augmedics is a company that develops augmented reality-guided surgical systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2014, the company is headquartered in Yoqneam Ilit, Israel, with an additional office located in Chicago, Illinois. Its flagship product, the xvision-spine (XVS) system, features a head-mounted display that allows surgeons to visualize the patient's anatomy through skin and tissue, significantly improving their ability to navigate during complex surgeries. The system integrates real-time positioning of surgical tools and utilizes illumination to enhance the focus area, providing critical insights and assistance to surgeons throughout the procedure. Augmedics strives to revolutionize surgical treatment by leveraging advanced technology to improve healthcare delivery.

LeafLink operates a wholesale management platform designed to connect cannabis brands and retailers, facilitating streamlined ordering processes, simplified communication, and reduced administrative tasks. The company's platform offers tools for driving brand awareness, boosting sales, tracking orders, engaging with customers, and managing logistics partners. LeafLink serves over 1,200 brands and 3,500 retailers across 22 territories in the US and Canada. Founded in 2015 and headquartered in New York, LeafLink also maintains offices in Los Angeles, San Francisco, Denver, Austin, and Toronto.

Kindred Motorworks specializes in modernizing vintage vehicles by integrating contemporary powertrains, safety features, and advanced technologies while preserving their classic aesthetics. The company dedicates significant effort to prototyping and meticulously assessing design choices to enhance performance and reliability across its models. By offering services that include the installation of modern features such as disc brakes and Bluetooth sound systems, Kindred Motorworks caters to customers seeking a blend of nostalgia and modern functionality. Additionally, the company focuses on converting internal combustion vehicles to electric power, facilitating the transformation of classic cars into modern, eco-friendly automobiles.

Provi is a Chicago-based company that operates the largest online marketplace for the wholesale alcohol industry. Founded in 2016, Provi connects buyers, such as liquor stores, bars, and restaurants, with distributors and suppliers, simplifying the historically complex ordering process. The platform enhances communication and operational efficiency for both on-premise and off-premise buyers by centralizing orders and providing tracking and analytics tools. With a presence in key U.S. markets, Provi serves about 10 percent of licensed retailers, contributing to significant time and cost savings while reducing errors in the ordering process. The company has been recognized for its workplace culture and has formed strategic partnerships to further enhance its service offerings. Through its innovative approach, Provi is reshaping the wholesale alcohol landscape.

PROCEPT BioRobotics Corporation is a surgical robotics company based in Redwood Shores, California, dedicated to advancing patient care in urology. The company develops, manufactures, and sells the AquaBeam Robotic System, an advanced image-guided surgical robotic system designed for minimally invasive procedures. Its primary focus is on treating benign prostatic hyperplasia (BPH), a common condition affecting approximately 40 million men in the United States, which causes lower urinary tract symptoms (LUTS). The company’s Aquablation therapy offers effective and durable solutions that are independent of prostate size, shape, or surgeon experience. PROCEPT has built a substantial clinical foundation for its offerings, evidenced by nine clinical studies and over 100 peer-reviewed publications highlighting the benefits and advantages of Aquablation therapy. Revenue is primarily generated from the sales of the AquaBeam Robotic System and the related single-use disposable handpieces.

Provi is a Chicago-based company that operates the largest online marketplace for the wholesale alcohol industry. Founded in 2016, Provi connects buyers, such as liquor stores, bars, and restaurants, with distributors and suppliers, simplifying the historically complex ordering process. The platform enhances communication and operational efficiency for both on-premise and off-premise buyers by centralizing orders and providing tracking and analytics tools. With a presence in key U.S. markets, Provi serves about 10 percent of licensed retailers, contributing to significant time and cost savings while reducing errors in the ordering process. The company has been recognized for its workplace culture and has formed strategic partnerships to further enhance its service offerings. Through its innovative approach, Provi is reshaping the wholesale alcohol landscape.

PROCEPT BioRobotics Corporation is a surgical robotics company based in Redwood Shores, California, dedicated to advancing patient care in urology. The company develops, manufactures, and sells the AquaBeam Robotic System, an advanced image-guided surgical robotic system designed for minimally invasive procedures. Its primary focus is on treating benign prostatic hyperplasia (BPH), a common condition affecting approximately 40 million men in the United States, which causes lower urinary tract symptoms (LUTS). The company’s Aquablation therapy offers effective and durable solutions that are independent of prostate size, shape, or surgeon experience. PROCEPT has built a substantial clinical foundation for its offerings, evidenced by nine clinical studies and over 100 peer-reviewed publications highlighting the benefits and advantages of Aquablation therapy. Revenue is primarily generated from the sales of the AquaBeam Robotic System and the related single-use disposable handpieces.

Theatro is a software company that specializes in developing business applications for wearable computing devices aimed at enhancing the productivity and communication of indoor mobile workforces, particularly in the retail and hospitality sectors. Theatro offers a range of solutions, including cloud services, wearable computers, indoor location capabilities, and analytics tools. The company's platform utilizes artificial intelligence and voice control to facilitate real-time communication and management for hourly workers, enabling businesses to optimize employee performance and operational efficiency. Established in 2011 and initially based in Menlo Park, California, Theatro has relocated its headquarters to Richardson, Texas, while also maintaining an office in Bengaluru, India. Theatro is recognized for its innovative approach to user context and data collection, which supports decision-making and enhances interaction with artificial intelligence systems.

PROCEPT BioRobotics Corporation is a surgical robotics company based in Redwood Shores, California, dedicated to advancing patient care in urology. The company develops, manufactures, and sells the AquaBeam Robotic System, an advanced image-guided surgical robotic system designed for minimally invasive procedures. Its primary focus is on treating benign prostatic hyperplasia (BPH), a common condition affecting approximately 40 million men in the United States, which causes lower urinary tract symptoms (LUTS). The company’s Aquablation therapy offers effective and durable solutions that are independent of prostate size, shape, or surgeon experience. PROCEPT has built a substantial clinical foundation for its offerings, evidenced by nine clinical studies and over 100 peer-reviewed publications highlighting the benefits and advantages of Aquablation therapy. Revenue is primarily generated from the sales of the AquaBeam Robotic System and the related single-use disposable handpieces.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Plano, Texas, that specializes in developing novel therapeutics for serious and life-threatening diseases. The company targets molecular pathways involved in cellular metabolism and inflammation, with a focus on conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension, and neurodegenerative diseases. Reata's pipeline includes bardoxolone methyl, which is undergoing Phase III trials for CKD caused by Alport syndrome and for pulmonary arterial hypertension associated with connective tissue disease. Additionally, omaveloxolone is in Phase II trials for Friedreich’s ataxia. The company is also exploring RTA 901 for neurological conditions and has RORgT inhibitors in preclinical development for autoimmune and inflammatory diseases. Reata has established strategic collaborations for the development and commercialization of its therapies in various Asian markets and with AbbVie for certain Nrf2 activators. Founded in 2002 and rebranded in 2005, Reata Pharmaceuticals is committed to advancing innovative treatments for complex medical challenges.

Semantra makes it possible to have an intelligent conversation with your enterprise databases, immediately improving the value of critical business applications like CRM, BI and ERP solutions. Semantra extends traditional BI and enterprise search applications by empowering users to quickly and easily access precise, critical information contained in enterprise databases through a familiar search box and using the language of your business. The company was founded in 2003 and is based in Addison, Texas. On June 21, 2009, Semantra, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Semantra makes it possible to have an intelligent conversation with your enterprise databases, immediately improving the value of critical business applications like CRM, BI and ERP solutions. Semantra extends traditional BI and enterprise search applications by empowering users to quickly and easily access precise, critical information contained in enterprise databases through a familiar search box and using the language of your business. The company was founded in 2003 and is based in Addison, Texas. On June 21, 2009, Semantra, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Plano, Texas, that specializes in developing novel therapeutics for serious and life-threatening diseases. The company targets molecular pathways involved in cellular metabolism and inflammation, with a focus on conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension, and neurodegenerative diseases. Reata's pipeline includes bardoxolone methyl, which is undergoing Phase III trials for CKD caused by Alport syndrome and for pulmonary arterial hypertension associated with connective tissue disease. Additionally, omaveloxolone is in Phase II trials for Friedreich’s ataxia. The company is also exploring RTA 901 for neurological conditions and has RORgT inhibitors in preclinical development for autoimmune and inflammatory diseases. Reata has established strategic collaborations for the development and commercialization of its therapies in various Asian markets and with AbbVie for certain Nrf2 activators. Founded in 2002 and rebranded in 2005, Reata Pharmaceuticals is committed to advancing innovative treatments for complex medical challenges.

Semantra makes it possible to have an intelligent conversation with your enterprise databases, immediately improving the value of critical business applications like CRM, BI and ERP solutions. Semantra extends traditional BI and enterprise search applications by empowering users to quickly and easily access precise, critical information contained in enterprise databases through a familiar search box and using the language of your business. The company was founded in 2003 and is based in Addison, Texas. On June 21, 2009, Semantra, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.